Related references
Note: Only part of the references are listed.Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein
Qingkai Yang et al.
CANCER CELL (2010)
Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy
Alison K. Ramsay et al.
CLINICAL SCIENCE (2009)
ERK5 is a Target for Gene Amplification at 17p11 and Promotes Cell Growth in Hepatocellular Carcinoma by Regulating Mitotic Entry
Keika Zen et al.
GENES CHROMOSOMES & CANCER (2009)
miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice
Cyrielle Clape et al.
PLOS ONE (2009)
The regulation of matrix metalloproteinases and their inhibitors
Ian A. Clark et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2008)
Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation
Inmaculada Ayala et al.
JOURNAL OF CELL SCIENCE (2008)
Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer
S. R. C. McCracken et al.
ONCOGENE (2008)
The MAP kinase ERK5 binds to and phosphorylates p90 RSK
Aarati Ranganathan et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2006)
Regulation of cellular functions by the ERK5 signalling pathway
X Wang et al.
CELLULAR SIGNALLING (2006)
Dominant negative FTase (DNFTα) inhibits ERK5, MEF2C and CREB activation in adipogenesis
G Sharma et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2005)
Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
ACP Riddick et al.
BRITISH JOURNAL OF CANCER (2005)
Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway
X Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: Efficacy of flt3 ligand immunotherapy
KD Somers et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
FGF8 isoform b expression in human prostate cancer
V Gnanapragasam et al.
BRITISH JOURNAL OF CANCER (2003)
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion
PB Mehta et al.
ONCOGENE (2003)
Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1
MS Squires et al.
BIOCHEMICAL JOURNAL (2002)
Strategies for MMP inhibition in cancer:: Innovations for the post-trial era
CM Overall et al.
NATURE REVIEWS CANCER (2002)
Complex roles of tissue inhibitors of metalloproteinases in cancer
YF Jiang et al.
ONCOGENE (2002)
Quantitative reverse transcription-polymerase chain reaction (RT-PCR): A comparison of primer-dropping, competitive, and real-time RT-PCRs
SJ Wall et al.
ANALYTICAL BIOCHEMISTRY (2002)
New functions for the matrix metalloproteinases in cancer progression
M Egeblad et al.
NATURE REVIEWS CANCER (2002)
Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells
Z Dong et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway
N Mody et al.
FEBS LETTERS (2001)
Mammalian MAP kinase signalling cascades
LF Chang et al.
NATURE (2001)
The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)
AA Troussard et al.
ONCOGENE (2000)
Share Paper
